Your browser doesn't support javascript.
loading
Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses.
Gunn, Bronwyn M; Roy, Vicky; Karim, Marcus M; Hartnett, Jessica N; Suscovich, Todd J; Goba, Augustine; Momoh, Mambu; Sandi, John Demby; Kanneh, Lansana; Andersen, Kristian G; Shaffer, Jeffrey G; Schieffelin, John S; Garry, Robert F; Grant, Donald S; Alter, Galit.
Affiliation
  • Gunn BM; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts.
  • Roy V; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts.
  • Karim MM; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts.
  • Hartnett JN; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana.
  • Suscovich TJ; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts.
  • Goba A; Viral Hemorrhagic Fever Program, Kenema Government Hospital.
  • Momoh M; Viral Hemorrhagic Fever Program, Kenema Government Hospital.
  • Sandi JD; Eastern Polytechnic University, Kenema, Sierra Leone.
  • Kanneh L; Viral Hemorrhagic Fever Program, Kenema Government Hospital.
  • Andersen KG; Viral Hemorrhagic Fever Program, Kenema Government Hospital.
  • Shaffer JG; Department of Immunology and Microbiology, Scripps Research Institute.
  • Schieffelin JS; Scripps Research Translational Institute, La Jolla, California.
  • Garry RF; Department of Biostatistics and Bioinformatics, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana.
  • Grant DS; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana.
  • Alter G; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana.
J Infect Dis ; 221(1): 156-161, 2020 01 01.
Article in En | MEDLINE | ID: mdl-31301137
Monoclonal antibodies can mediate protection against Ebola virus (EBOV) infection through direct neutralization as well as through the recruitment of innate immune effector functions. However, the antibody functional response following survival of acute EBOV disease has not been well characterized. In this study, serum antibodies from Ebola virus disease (EVD) survivors from Sierra Leone were profiled to capture variation in overall subclass/isotype abundance, neutralizing activity, and innate immune effector functions. Antibodies from EVD survivors exhibited robust innate immune effector functions, mediated primarily by IgG1 and IgA1. In conclusion, development of functional antibodies follows survival of acute EVD.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunoglobulin G / Hemorrhagic Fever, Ebola / Antibodies, Neutralizing / Immunity, Innate / Antibodies, Viral Limits: Humans Country/Region as subject: Africa Language: En Journal: J Infect Dis Year: 2020 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunoglobulin G / Hemorrhagic Fever, Ebola / Antibodies, Neutralizing / Immunity, Innate / Antibodies, Viral Limits: Humans Country/Region as subject: Africa Language: En Journal: J Infect Dis Year: 2020 Type: Article